Stockscreener 앱 받기
1.17
2.50%
-0.03
시간 외 거래:
1.18
0.01
+0.85%
Cardiff Oncology Inc 주식(CRDF)의 최신 뉴스
Cardiff Oncology Inc (CRDF) Stock Price Target & Forecast - TradingKey
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from S&P Global BMI Index - marketscreener.com
Cardiff Oncology Shares Rise After Upgrade From HC Wainwright - marketscreener.com
HC Wainwright Upgrades Cardiff Oncology to Buy From Neutral, Price Target is $9 - marketscreener.com
CRDF: Settlement enables global phase III launch for onvansertib in RAS mutated colorectal cancer - TradingView
Form 8K Cardiff Oncology Inc For: 14 September By Investing.com - Investing.com Canada
Cardiff Oncology settles dispute with NMS over onvansertib rights By Investing.com - Investing.com India
Cardiff Oncology Inc. (CRDF) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Cardiff Oncology, Inc. (CRDF) Presents at 8th Annual RAS-Targeted Drug Development SummitSlideshow (NASDAQ:CRDF) 2026-09-10 - Seeking Alpha
Cardiff Oncology (CRDF) Slips to $1.02 as Biotech Stock Holds Above Key SupportNarrow Range Breakout - dars.gov.et
Cardiff Oncology Announces Upcoming Conference Participation for Mani Mohindru, Ph.D. - Quiver Quantitative
Cardiff Oncology to Participate in September 2026 Conferences - GlobeNewswire
Cardiff Oncology Inc. (CRDF) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cardiff Oncology (NASDAQ: CRDF) seeks share boost that may dilute holders - stocktitan.net
Equities Analysts Offer Predictions for CRDF Q3 Earnings - MarketBeat
Cardiff Oncology Inc (CRDF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enterprise value to EBIT forward of Cardiff Oncology, Inc. – DUS:XE7C - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Cardiff Oncology (CRDF) asks investors to double authorized common shares - Stock Titan
Cardiff Oncology (CRDF) Holds Near $0.98 as Consolidation PersistsFibonacci Extension - vinanet.vn
CARDIFF ONCOLOGY, INC. : WILLIAM BLAIR CUTS TO MARKET PERFORM RATING - webull.com
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF) - The Globe and Mail
William Blair downgrades Cardiff Oncology (CRDF) to a Hold - The Globe and Mail
CRDF Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
William Blair Downgrades Cardiff Oncology to Market Perform From Outperform - marketscreener.com
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Maintains Target Price $6 - Moomoo
William Blair downgrades Cardiff Oncology stock rating on rights uncertainty - Investing.com
William Blair downgrades Cardiff Oncology stock rating on rights uncertainty By Investing.com - Investing.com Canada
Cardiff Oncology earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Is Cardiff Oncology Inc (CRDF) Moving in the Right Direction Aft - GuruFocus
Cardiff Oncology: Q2 Earnings Snapshot - AOL.com
Cardiff Oncology Q2 operating expenses fall on lower R&D costs - TradingView
Cardiff Oncology (NASDAQ:CRDF) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update - The Manila Times
Cardiff Oncology (NASDAQ: CRDF) cuts R&D spend but flags going concern risk - Stock Titan
Cardiff Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
CRDF Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage R&D BurnRevenue Guidance Update - vinanet.vn
Cardiff Oncology (CRDF) Holds at $0.85 After Modest Gain; Key Resistance at $0.89 in FocusPCR Spike - dars.gov.et
BlackRock, Inc. Slashes Cardiff Oncology (CRDF) Stake by 78.3% - GuruFocus
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Cardiff Oncology (CRDF) Expected to Post Quarterly Earnings on Tuesday - MarketBeat
Cardiff Oncology Inc (CRDF) Valuation: PE, PB & Fair Value Analysis - TradingKey
BlackRock (CRDF holder) discloses 863,259 Cardiff Oncology shares in 13G/A - Stock Titan
CRDF|Cardiff Oncology Inc|Price:0.952|Chg%:+0.023 - TradingKey
Cardiff Oncology Inc (CRDF) Balance Sheet - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.827|Chg%:-0.011 - TradingKey
Cardiff Oncology Inc (CRDF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cardiff Oncology Inc (CRDF) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cardiff Oncology Inc (CRDF) Institutional Confidence - TradingKey
Cardiff Oncology, Inc. Revenue Breakdown – NASDAQ:CRDF - TradingView
Cardiff Oncology Inc (CRDF) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardiff Oncology Inc (CRDF) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cardiff Oncology Inc (CRDF) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cardiff Oncology Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Cardiff Oncology Inc (CRDF) Cash Flow - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.831|Chg%:+0.004 - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.845| - TradingKey
TradingKey - TradingKey
CRDF Q2'26 Earnings: revenue estimate is 62.78K USD - TradingView
Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
CRDF Q1 2026 Earnings: EPS Misses Estimates as Development-Stage Company Reports No Revenue - careplusvn.com
1.73%
1.36%
자본화:
|
볼륨(24시간):